Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal

MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc.

MIRA

0.00
  • Mira Pharmaceuticals executed an amended exclusive license with MIRALOGX, securing worldwide exclusive rights to MIRA-55 and SKNY-1.
  • Deal grants global development, commercialization, sublicensing, IP enforcement rights for both assets, tightening control of the company’s pipeline.
  • MIRA-55 is an oral investigational candidate for chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders.
  • Amendment leaves previously disclosed core economic terms of existing license arrangements largely unchanged.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606040800ACCESSWRNAPR_____1173065) on June 04, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.